Palantir's 104% U.S. Revenue Growth: Key Metric But Valuation Remains Stretched

What happened

Palantir's Q1 2026 U.S. commercial revenue surged 133% year-over-year, and overall U.S. revenue grew 104%, reinforcing the narrative of accelerating domestic demand. However, as our DeepValue report details, the stock at ~$127 already prices in sustained hypergrowth, with a P/E of 132x and no margin of safety. The filings show remaining deal value is option-heavy and subject to termination, meaning backlog growth may not convert linearly to revenue. While the commercial engine is firing, government revenue remains dependent on appropriations, and the NHS contract adds political risk. The next quarter's guidance and U.S. commercial RDV growth will be critical to validate the premium multiple.

Implication

For investors, the 104% U.S. revenue growth is a positive data point that aligns with management's narrative of successful AI platform adoption in the domestic commercial sector. However, the stock's current price already reflects this optimism and more, leaving little room for error. Key risks include the option-heavy remaining deal value not converting to revenue, potential headwinds from the $5.6B cloud commitment, and the upcoming NHS renewal test in March 2027. Until the next quarterly report confirms sustained customer growth and guidance durability, the risk-reward remains unfavorable. A disciplined approach is to wait for either a pullback to the attractive entry range or for concrete evidence that RDV conversion is accelerating without margin degradation.

Thesis delta

The news does not alter the core thesis but highlights that U.S. commercial acceleration remains the primary driver of growth expectations. The key shift to monitor is whether this hypergrowth can be sustained without margin deterioration, especially given the increased cloud cost obligations. Until then, the thesis stands: Palantir has a strong product but the stock is fully priced.